Fundraising FoxMercury Fund — 2020 Investments
7 investments dated 2020 · listed companies and verified rows first · show all
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesPremier PartnersSoftBank Vision Fund+12 more
Aclaimant provides risk management software to help organizations identify and actively manage business risks.
Enterprise SoftwareInsurTechChicago, US
Michael Schultz(Co-founder)inDavid Wald(Executive Officer, Director)inJim Farber(Founder)in
BoardLaura Brady(Director)
Board seatAdrian Fortino· per SEC Form D
Co-investors1809 CapitalAspen Capital GroupLightbankModerne VenturesNext Coast VenturesRoyal Street Ventures Management Company, Llc+4 more
Otto is an all-in-one client communication platform for veterinary clinics, combining reminders, forms, payments, messaging, AI scribing, and online booking into a single subscription.
Digital HealthSaaS
StevenPrice
Co-investorsAtento CapitalDundee Venture CapitalHarmony PartnersPravega Ventures
Ripple Science offers EnrollNow, a HIPAA-compliant, SOC 2-certified platform for managing research participant prescreening, enrollment, scheduling, and communication.
Digital HealthHealthtechSaaS
Co-investorsDundee Venture CapitalID VenturesInvest MichiganMichigan Capital NetworkMichigan RiseNarrow Gauge Ventures+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CMT SolutionsOlea NetworksTrackx Holdings
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.